NAD+ for Sale USA: A 1,000 mg Vial That Clears No Border

The two routes share a product page and share very little else. Set them side by side on the things that are not the price.

The recourse rows matter more on this compound than on most, and it is a matter of order size. A gram is a large single unit of value. A disputed 10 mg peptide vial at $24.50 is a bad afternoon; a disputed multi vial NAD+ order that cleared the $250 free carriage threshold is a real amount of money sitting with a counterparty you cannot reach.

FDA's own personal importation guidance is the plain statement of why the import route is not a settled one. It says that in most circumstances it is illegal for individuals to import drugs into the US for personal use, because such products often have not been approved here, and that products violating FDA laws or regulations are "generally not permitted", though agency personnel "may consider a more permissive decision" in a defined set of situations. Discretion is not a guarantee, and a parcel that is not released does not come back as store credit.

This is the point where domestic supply pages usually overstate their case, so it is worth being exact about what the risk is and is not.

Lyophilised material ships dry. Dry powder tolerates ambient transit far better than a solution does, which is precisely why research material is sold lyophilised in the first place. A two day domestic parcel arriving warm is not the disaster the phrase cold chain implies, and anybody telling you otherwise is selling shipping insurance.

The real exposure is the tail. A shipment held for weeks somewhere unlogged, at an unknown temperature, in unknown humidity, has a storage history nobody can reconstruct, and there is no test you can run on arrival that reads it back. The domestic argument is not that the parcel stays cold. It is that the interval short enough to reason about is the only interval you can reason about.

Once material is in solution the calculus inverts and refrigeration becomes the whole story, which is one argument for not making up a full gram in one go without a plan for it. Handling and storage figures for this compound sit on our NAD reference page and the general rules on the storage guide.

The phrase is easy to print and cheap to imply. Four checks separate a domestic stock position from a domestic mailing address.

• A dispatch cut-off, in a named timezone. Same day before 2pm CST is an operational commitment that only a warehouse holding stock can make. Ships within 5 to 10 business days usually describes a company waiting on somebody else's shipment.
• Where the first tracking scan happens. A domestic carrier accepting the parcel in a US city is evidence. A tracking number that sits in pre-advice for a week and then appears at an international gateway is evidence of something else.
• A physical return address in the US. Not a contact form, not a support inbox, an address a return can actually be posted to.
• A refund position written down before you buy it. The terms that exist on the day of the dispute are the ones published before it.

One thing this check cannot tell you is where the material was made, which is a different question with a different answer. Domestic stock means the vial was warehoused and dispatched in the US. The bulk substance behind it moves through a global wholesale market regardless, which is exactly why the batch certificate does work that the shipping origin cannot. Our supplier criteria page takes the full checklist apart.

Searches for NAD+ in the USA collapse two markets that are regulated in completely different places, and keeping them apart saves a lot of confusion.

The clinic side is where state law lives. Who may administer an intravenous infusion, under what supervision, on whose order, and what a facility must be licensed as are questions answered by state medical practice acts, nursing boards and pharmacy boards, and the answers genuinely differ between states. A drip bar that operates in one state under one arrangement may operate in another under a different one. That is why the local NAD+ market looks patchy in a way the mail order market does not, a pattern our local page goes into.

The federal side is where the compounding position lives, and it does not vary by state. On FDA's category lists for bulk substances nominated under section 503A, updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) appears in category 1, bulk drug substances under evaluation, alongside Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH). There is no NAD entry in category 2. Category 1 means FDA does not intend to act against a compounder using the substance provided the conditions in its guidance are met: non-enforcement while an evaluation runs, not approval, and not permanent. A separate entry, Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate, sits in category 3 on the same document, which is a trap worth knowing about because it reads like the same substance.

The vial side is the simplest of the three. Research material labelled for laboratory use is sold against an order, not dispensed against a prescription, and the transaction does not change as you cross a state line. Our regulatory page sets out the three positions properly.

A short parcel journey improves the odds on handling and does nothing at all for what was in the vial when it was filled. On NAD+ specifically, that gap has a documented consequence attached.

FDA's compounding notice, content current as of 30 October 2024, states that the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products", that food-grade ingredients "are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins", and that it received adverse event reports after use of NAD+ injectable drugs including "severe chills, shaking, vomiting and fatigue with some requiring medical treatment", consistent with excessive endotoxin levels. Every repackager in that sentence was a domestic one.

So the domestic question and the testing question are independent, and the second is the one that matters more. Ask for a batch-specific certificate, check the batch code on it against the code printed on the vial, and read what was actually tested. Identity and purity by HPLC and mass spec do not answer an endotoxin question; a bacterial endotoxins result does. Ascension publishes two third-party assays against this listing, from Kovera Labs on batch 25-05260628 tested 14 June 2026 and MZ Biolabs on batch 25-01260229 tested 26 January 2026.

Domestic ordering makes the total predictable, which is the only reason a landed figure is worth calculating at all.

Note where the threshold falls once the code is applied. Free carriage starts at $250, so at $52.00 a vial it takes five vials to clear it and four leaves you $42.00 short. Whether the cart measures the threshold before or after the code is a checkout rule rather than a published one.

A flat charge is the only import-style cost left on a domestic order, and it behaves the way fixed costs always do. A $12.00 carriage charge divides by the ten lots of 100 mg in one vial and adds $1.20 to each, taking $5.20 to $6.40 and eating 23% of the discount. Across five vials that clear the threshold it adds nothing. The rest of the arithmetic, including the residual volume left in the vial, is on the NAD+ price page, and the code itself is broken down on the coupon page.